Angiogenesis inhibition for glioblastoma at the edge: Beyond AVAGlio and RTOG 0825

Neuro-Oncology

Volumn 15, Issue 8, 2013, Pages 971-

  Weller, Michael ^a   Yung, W K Alfred ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ANTIANGIOGENIC ACTIVITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; EDITORIAL; GLIOBLASTOMA; HUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84880663605     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not106     Document Type: Editorial

References (3)

1. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAGlio. Neuro-Oncology 2012;14:Suppl 6(vi101-vi105).
2. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013; 31:Suppl(abstr 1).
3. Wick W, Cloughesy TF, Nishikawa R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolo-mide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31:Suppl(abstr 2002).